Literature DB >> 8575858

Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow.

K Hori1, Q H Zhang, H C Li, S Saito, Y Sato.   

Abstract

Blood flows of normal tissues (subcutis, liver, kidney cortex, bone marrow) and tumor tissues (SLC) were measured during a daytime period (3-9 HALO) and a nighttime period (15-21 HALO) by the hydrogen clearance technique. Rats were subjected to an artificial light-dark cycle with light from 7 A.M. to 7 P.M. In all normal tissues, there were no significant differences between average tissue blood flows in 2 different time zones, while tumor tissue blood flow increased significantly in the nighttime. Based on this functional characteristic of tumor microcirculation, anti-tumor effects were compared between a group in which ADM was administered at 4 HALO and a group in which it was administered at 16 HALO. The therapeutic effect of ADM on rats administered at 16 HALO was significantly greater, particularly in large tumors, than that on rats administered at 4 HALO. The main reason for this therapeutic improvement may be due to the selective increase in delivery of anti-cancer drugs to tumor tissues brought about by a circadian increase in tumor tissue blood flow.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8575858     DOI: 10.1002/(SICI)1097-0215(19960126)65:3<360::AID-IJC14>3.0.CO;2-E

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Importance of circadian timing for aging and longevity.

Authors:  Victoria A Acosta-Rodríguez; Filipa Rijo-Ferreira; Carla B Green; Joseph S Takahashi
Journal:  Nat Commun       Date:  2021-05-17       Impact factor: 14.919

2.  Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride.

Authors:  K Hori; S Saito; H Takahashi; H Sato; H Maeda; Y Sato
Journal:  Jpn J Cancer Res       Date:  2000-02

3.  Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

Authors:  K Hori; S Saito; Y Nihei; M Suzuki; Y Sato
Journal:  Jpn J Cancer Res       Date:  1999-09

4.  A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Authors:  K Hori; S Saito; K Kubota
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

5.  The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day.

Authors:  Kai Yang; Ningbo Zhao; Dan Zhao; Dan Chen; Yadong Li
Journal:  Drug Des Devel Ther       Date:  2013-06-20       Impact factor: 4.162

6.  Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.

Authors:  K Hori; S Saito
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

7.  Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo.

Authors:  Niu Zhanfeng; Li Yanhui; Fei Zhou; Hao Shaocai; Li Guangxing; Xia Hechun
Journal:  Oncotarget       Date:  2015-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.